CRISPR Therapeutics
CRSP
CRSP
470 hedge funds and large institutions have $4.52B invested in CRISPR Therapeutics in 2021 Q3 according to their latest regulatory filings, with 58 funds opening new positions, 193 increasing their positions, 117 reducing their positions, and 79 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
470
Holders Change
-25
Holders Change %
-5.05%
% of All Funds
8.25%
Holding in Top 10
2
Holding in Top 10 Change
-10
Holding in Top 10 Change %
-83.33%
% of All Funds
0.04%
New
58
Increased
193
Reduced
117
Closed
79
Calls
$294M
Puts
$392M
Net Calls
-$98.1M
Net Calls Change
-$36.9M
Top Buyers
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$28.8M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$28.6M |
| 3 |
Goldman Sachs
New York
|
+$28.1M |
| 4 |
AC
Armistice Capital
New York
|
+$24.8M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$19.6M |
Top Sellers
| 1 |
Two Sigma Advisers
New York
|
-$76.6M |
| 2 |
Two Sigma Investments
New York
|
-$47.6M |
| 3 |
Capital International Investors
Los Angeles,
California
|
-$46.3M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$21.3M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$19.6M |
